A randomised, double blind, placebo-controlled study evaluating the effect of L. reuteri DSM 17938 on the number of days of sick leave related to respiratory and/or gastrointestinal diseases among male steelworkers.

242 subjects were randomised to ingest L. reuteri (10^8 CFU/day) or the matching placebo for 90 days, whereof 79 and 80 completed the study, respectively.

L. reuteri significantly reduced the incidence of diarrhoea, which was reported on 0.60 days for subjects of the L. reuteri group vs. 1.33 days in the placebo group. There was no difference in primary outcome of  number of sick days due to respiratory or gastrointestinal symptoms. The drop-out rate of randomized subjects was 34%.  

Conclusion: The incidence of diarrhoea was significantly reduced by the daily intake of L. reuteri DSM 17938, but there was no effect on the number of days of sick leave related to respiratory and/or gastrointestinal disease.



Schröder C, Schmidt S, Garbe E, Röhmel J, Giersiepen K. Effects of the regular intake of the probiotic Lactobacillus reuteri (DSM 17938) on respiratory and gastrointestinal infections in a workplace setting: a double-blind randomized placebo-controlled trial. BMC Nutrition 2015;1:3. 

Crawling baby

For the avoidance of doubt, BioGaia’s products are food supplements, and the information on this part of the website should not be interpreted as our products are intended to diagnose, treat, cure or prevent any disease.

The information on this part of the website is intended only for health care and business professionals. If you are not a health care or business professional and would like to learn more about the indications BioGaia works with, please visit our Expertise pages.

Please read terms & conditions before accepting. By clicking on the button “I acknowledge and accept” you confirm that you are a healthcare or business professional and have read and understood this disclaimer including the terms and conditions.